TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Allopurinol in Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* angiographically documented coronary artery disease,~* a positive exercise tolerance test (ETT)~* a history of symptoms of chronic, stable, effort-induced angina for ≥ 2 months.~* All concomitant antianginal medication will be allowed and continued unchanged during the study.~Exclusion Criteria:~* the inability to do an ETT due to back or leg problems,~* myocardial infarction or acute coronary syndrome ≤ 2 months,~* coronary revascularization (percutaneous or CABG) ≤ 6 months,~* Left Ventricular Ejection Fraction \<45%,~* estimated GFR \<60 ml/min or creatinine \>180 mmol/ml,~* significant valvular pathology,~* already had gout or on allopurinol,~* atrial arrhythmias or ECG abnormalities interfering with ST-segment interpretation,~* previous ventricular arrhythmias on ETT,~* severe hepatic disease~* or on azathioprine, 6 mercaptopurine or warfarin.~* Patients who have participated in any other clinical trial within the previous 30 days will be excluded.~* Patients who are unable to give informed consent will also be excluded from this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Allopurinol High dose (Type: EXPERIMENTAL): None
- Allopurinol Low dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of an Internet-based Platform for Monitoring Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* daily Internet access~* able to provide informed consent~* able to read, write and understand English without difficulty~Exclusion Criteria:~* have significant co-morbidities that may interfere with effective HF management~* reside in a nursing home~* have a disability that precludes walking~* patients in who it is foreseen will be unlikely to survive for the duration of the study or have scheduled surgical procedures that based on the opinion of their hospital attending physician should be excluded

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vHFC (Type: EXPERIMENTAL): Patients will get to participate in the interactive heart failure website (vHFC).
- Usual Care (Type: NO_INTERVENTION): Patients will not get to participate in the interactive heart failure website (vHFC).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SAFE-PCI for Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have the capacity to understand and sign an informed consent form~* Age ≥ 18 years~* Female patient undergoing urgent or elective PCI or undergoing diagnostic angiography to evaluate ischemic symptoms with the possibility of PCI~Exclusion Criteria:~* Peripheral arterial disease that prohibits vascular access~* Bilateral abnormal Barbeau tests~* Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (note that the opposite arm may be used for radial access in case a dialysis graft is present in one arm provided that the opposite arm has a normal Barbeau test)~* International normalized ratio (INR) ≥ 1.5 in a patient treated with oral vitamin K antagonists (i.e., warfarin).~* Receipt of oral Factor Xa or IIa inhibitors ≤ 24 hours prior to the procedure~* Planned staged PCI within 30 days of index procedure~* Valvular heart disease requiring valve surgery~* Planned right-heart catheterization~* Primary PCI for ST-segment elevation myocardial infarction~* Presence of bilateral internal mammary artery coronary bypass grafts~* Unable to provide informed consent~* Participation in any investigational drug or device study currently or within 30 days prior to enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transradial PCI (Type: OTHER): None
- Transfemoral PCI (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* uncontrolled persistent asthmatics on daily inhaled corticosteroids (GINA)~Exclusion Criteria:~* viral/fungal/bacterial infection +fever (\<1 month)~* asthma exacerbation (\<3 months)~* other respiratory disease (CF, ciliary dyskinesia,bronchiectasis)~* cardiac patients using beta-blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: ACTIVE_COMPARATOR): None
- long-acting beta2-mimetic (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal women 18-50 years of age~2. Requiring gonadrotropin-releasing hormone agonist for any indication except ovulation induction~3. If there is abnormal uterine bleeding, such bleeding is not obviously related to structural defects such as polyps or submucous leiomyomas; subserosal and intramural myomas (International Federation of Gynecology and Obstetrics Classification 3-8 inclusive) are acceptable~Exclusion Criteria:~1. Currently pregnant~2. Recent used of gonadrotropin-releasing hormone agonist~   1. 1 month depot formulation eg leuprolide acetate 3.75, within 90 days~  2. 3 month depot formulation eg leuprolide acetate 11.25 within 180 days~3. Currently has an intrauterine contraceptive device~4. Currently on gonadal steroids (including birth control pills, rings, or implantable or injectable agents)~5. History of breast cancer~6. Currently undergoing ovulation induction~7. History of adverse reactions to gonadal steroids~8. Hemoglobin \<8 mg/dl as measured within 30 days of enrollment (Baseline hemoglobin is standard of care for patients initiating gonadrotropin-releasing hormone agonist therapy)~9. Weight above \>250 lbs~10. Has a known submucous leiomyoma ( International Federation of Gynecology and Obstetrics Class type 0, 1, 2)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- medroxyprogesterone acetate (Type: ACTIVE_COMPARATOR): None
- control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for video-assisted thoracic surgery for clinical diagnosis of spontaneous pneumothorax~* Must be able to swallow tablets 1 h before surgery~* American Society of Anesthesiologists (ASA) physical status class I or II~Exclusion Criteria:~* Known allergy or other contraindications to study drugs~* Acute myocardial infarction ≤6 months before enrollment~* Serum creatinine \> 2 mg/dL~* Body mass index (BMI) \> 30~* Diagnosis of psychiatric disorders~* Known or possible pregnancy~* Epilepsy~* Chronic opioid therapy or abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Control intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
- CROxy (Type: EXPERIMENTAL): The intervention group will receive controlled-release oxycodone 1 h pre-operatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CD of the ileum, with or without involvement of the caecum or the right colon~* Colonoscopy showing active lesions defined by a CDEISm score \>6~* Informed consent to participate in this study~* Prescription of steroid treatments : Budesonide, Prednisone (or Prednisolone) independently from entry in study~* Patients who respond to budesonide (initial dose 9 mg/d) or prednisone or prednisolone (initial dose 40 mg/d), defined as a 70 points decrease in CDAI between the pre-inclusion and the inclusion visit,~* Patients colonized with AIEC on initial ileal biopsies.~Exclusion Criteria:~* Ileal stenosis that cannot be crossed by the endoscope,~* Infliximab treatment received less than 8 weeks before inclusion in this study,~* Adalimumab treatment received less than 4 weeks before inclusion in this study,~* Vedolizumab treatment received less than 8 weeks before inclusion in the study,~* Hypersensitivity to Ciprofloxacin, to other quinolones, or to any of the excipients (cellulose microcrystalline, crospovidone, maize starch, magnesium stearate, silica colloidal anhydrous,, hypromellose titanium dioxide E171, macrogol 4000,),~* Tizanidine, Probenecid, Theophylline, Xanthine derivatives, Phenytoin, oral anticoagulants, and Ropinirole treatment,~* Hypersensitivity to Rifaximin, or to any excipients (sodium starch glycolate type A, glycerol distearate, colloidal anhydrous silica, talc, microcrystalline cellulose, hypromellose, titanium dioxide, disodium edentate, propylene glycol, red iron oxide E172),~* Previous extensive ileal surgery (≥ 1 meter as measured on the pathology and/or surgical report),~* Short bowel syndrome,~* Need for an intestinal resection for fistula, abscess or intestinal obstruction,~* Renal failure (creatinine clearance\<30 mL/min/1.73m2),~* Liver failure (V factor\<50%),~* Past history of epilepsy,~* No health insurance,~* Pregnant or lactating women,~* Refusal to have a double effective contraception,~* Patients already included in a biomedical research other than an observational study (e.g: registry, cohort).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): oral Ciprofloxacin 500 mg bid and oral Rifaximin 800 mg bid for 12 weeks
- Control arm (Type: PLACEBO_COMPARATOR): a placebo of Ciprofloxacin bid and a placebo of Rifaximin bid for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Three Good Things (3GT) - Intervention for Transitional Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals ≥ 18 years of age.~* Current inpatient at the Mayo Clinic Health System Bloomer Hospital, Bloomer, Wisconsin (a Swing Bed Hospital as defined by the Center for Medicare and Medicaid Services (CMS)).~* Able to speak English.~* Able to answer questionnaires.~Exclusion Criteria:~* Individuals \< 18 years of age.~* Patient unwilling or unable to provide consent to participate in this research study.~* Patient under guardianship.~* As determined through self-report, patient in active psychosis, active suicidal ideation, active substance abuse meeting criteria for substance use disorders except for nicotine (the exception is patients with a history of substance abuse that have been in remission for at least one full year).~* Patient diagnosed with obsessive-compulsive disorder, active panic disorder with agoraphobia or other phobic disorder, active Post Traumatic Stress Disorder, or active severe personality disorders.~* Patient with previous participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3GT journaling group (Type: EXPERIMENTAL): Subjects will participate in the Three Good Things (3GT) Positive Psychology journaling activity daily for six weeks.
- Non-journaling group (Type: NO_INTERVENTION): Subjects will not participate in the evening journal activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* infertile women with diminished ovarian reserve~Exclusion Criteria:~* women \> 45

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- Dehydroepiandrosterone (Type: OTHER): infertile women with low anti mullerian hormone levels

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of HbSC disease~* Score of 80 or lower on the AdultQLTM 3.0 Sickle Cell Disease Module, or any disease related complication, including, but not limited to, one or more pain events per year, proliferative sickle retinopathy, avascular necrosis, cholelithiasis, or any thrombotic event. If the subject has a score \>80, they may still enroll on the trial, and be analyzed for secondary endpoints. They will be excluded from analysis of the primary endpoint.~Exclusion Criteria:~* Failure to meet inclusion criteria~* Hydroxyurea usage in the last 3 months.~* Chronic RBC transfusion therapy~* Packed red blood cell transfusion in the last 3 months (temporary exclusion).~* Pregnancy, or refusal to use medically effective birth control if female and sexually active.~* Current phlebotomy therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxurea (Type: EXPERIMENTAL): Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary breast cancer~  * Advanced disease~* Radiographic confirmation of bone metastases (≥ 1 bone scan lesion must be confirmed as metastatic by plain radiographs or CT scan/MRI)~  * Must have received zoledronic acid to treat metastatic bone disease (i.e., ≥ 4 or 5 zoledronic acid treatments prior to study entry for patients receiving 4- or 3-weekly infusions, respectively) for ≥ 4 months prior to study entry~ * Any bisphosphonate to treat metastatic bone disease allowed provided it was not given for more than 12 months prior to study entry~* No metabolic bone disease (e.g., Paget's disease of bone)~  * Osteoporosis allowed~* No brain metastases~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Male or female~* Menopausal status not specified~* WHO or ECOG performance status 0-2~* Life expectancy ≥ 6 months~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* AST and ALT ≤ 3 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* Creatinine clearance ≥ 30 mL/min~* No poor venous access~* No concurrent active dental problems, including infection of the teeth or jawbone (maxilla or mandibular)~* No prior or current diagnosis of osteonecrosis of the jaw~* No other cancer within the past 5 years except nonmelanomatous skin cancer, carcinoma in situ of the uterine cervix, or superficial bladder cancer treated with curative intent~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No other prior bisphosphonate treatment within the past 3 weeks~* No treatment with systemic bone-seeking radioisotopes (e.g., strontium chloride Sr 89, samarium Sm 153 lexidronam pentasodium) within the past 3 months~* No wide-field (hemibody) radiotherapy within the past 3 months~  * Recent standard-field, localized radiotherapy allowed~* No dental or jaw surgery (e.g., extractions, implants) within the past 4 weeks~* No other concurrent bisphosphonates~* No concurrent medication with drugs known to affect bone metabolism (e.g., calcitonin or high-dose systemic corticosteroids \[\> 10 mg prednisolone/day or equivalent\])~  * Systemic or oral corticosteroids allowed for clearly indicated conditions (e.g., chemotherapy-induced emesis, brain metastases, compression syndromes)~* Concurrent chemotherapy, biological therapy, or endocrine therapy allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ejaculatory Abstinence on Semen Parameters in Male Factor Infertility Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male Age 18 - 50 years and female age \< 38 years~* First IVF cycle~* Abnormal semen parameters (at least 1 of the following on 2 semen analysis with at least one being in the past 12 months): a) sperm concentration \< 10 million/mL; b) unprocessed semen analysis with \< 10 million motile sperm or processed semen analysis with \< 3 million motile sperm; c) \< 2 % normal forms (strict Kruger morphology)~* Female AMH \> 0.7 and/or and day 2-4 FSH \< 12~Exclusion Criteria~* Donor sperm~* Males with less than 200,000/mL sperm in the ejaculate~* Utilization of a gestational carrier~* Frozen donor egg~* Female morbid obesity: BMI \> 40~* History of recurrent pregnancy loss (≥2 spontaneous abortions)~* Preimplantation genetic testing - (M or SR) Monogenetic disorders or chromosomal rearrangement~* The use of non-ejaculated sperm (testicular sperm extraction)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Routine care (Type: NO_INTERVENTION): Routine care is normally having men abstain from ejaculation from 2 to 5 days prior to the scheduled oocyte retrieval date. Men in the routine care arm will abstain from ejaculation greater than 48 hours before providing a semen sample the day of the scheduled oocyte retrieval.
- Ejaculatory abstinence less than 24 hours (Type: EXPERIMENTAL): Males will ejaculate within 24 hours of the scheduled oocyte retrieval date.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues